National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/28752

Target Organs and Levels of Evidence for GMM-07

Toxicology Studies of Allyl Bromide (CASRN 106-95-6) in Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Studies of Allyl Bromide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Allyl bromide
106-95-6
08/28/2006 Starting material/chemical intermediate in organic synthesis & intermediate in the manufacture of polymers/resins, synthetic perfumes, pharmaceuticals, agricultural chemicals, and other allyl compounds. Gavage
P53: 0, 0.5, 1, 2, 4 or 8 mg/kg; 15/sex/dose C57BL/6: 0 or 8 mg/kg; 15/sex/dose
BioReliance, Inc

Levels of evidence information for Gavage and Genetic Toxicology Studies of Allyl Bromide in C57BL/6 Mice
  Male C57BL/6 Mice Female C57BL/6 Mice
  40 Weeks 40 Weeks
Neoplastic Lesions None None
Non-Neoplastic Lesions None None

Levels of evidence information for Gavage and Genetic Toxicology Studies of Allyl Bromide in p53 Haploinsufficient Mice
  Male p53 Haploinsufficient Mice Female p53 Haploinsufficient Mice
  40 Weeks 40 Weeks
Levels of Evidence No evidence No evidence
Neoplastic Lesions None None
Non-Neoplastic Lesions None None




Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Allyl bromide
106-95-6
08/28/2006 Starting material/chemical intermediate in organic synthesis & intermediate in the manufacture of polymers/resins, synthetic perfumes, pharmaceuticals, agricultural chemicals, and other allyl compounds. Gavage
Tg.AC: 0, 0.5, 1, 2, 4, or 8 mg/kg; 15/sex/dose FVB/N: 0 or 8 mg/kg; 15/sex/dose
BioReliance, Inc

Levels of evidence information for Gavage and Genetic Toxicology Studies of Allyl Bromide in FVB/N Mice
  Male FVB/N Mice Female FVB/N Mice
  40 Weeks 40 Weeks
Neoplastic Lesions None None
Non-Neoplastic Lesions None None

Levels of evidence information for Gavage and Genetic Toxicology Studies of Allyl Bromide in Tg.AC Hemizygous Mice
  Male Tg.AC Hemizygous Mice Female Tg.AC Hemizygous Mice
  40 Weeks 40 Weeks
Neoplastic Lesions None
  • Skin, vulva: squamous cell papilloma 2/15 4/15 1/15 6/15 5/14 7/15
  • Skin, all site: squamous cell papilloma¬†4/15 6/15 3/15 7/15 8/14 9/15
Non-Neoplastic Lesions None None
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.